WO2005065661A3 - Immediate, controlled and sustained release formulations of galanthamine - Google Patents

Immediate, controlled and sustained release formulations of galanthamine Download PDF

Info

Publication number
WO2005065661A3
WO2005065661A3 PCT/US2004/040109 US2004040109W WO2005065661A3 WO 2005065661 A3 WO2005065661 A3 WO 2005065661A3 US 2004040109 W US2004040109 W US 2004040109W WO 2005065661 A3 WO2005065661 A3 WO 2005065661A3
Authority
WO
WIPO (PCT)
Prior art keywords
galanthamine
immediate
controlled
sustained release
release formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/040109
Other languages
French (fr)
Other versions
WO2005065661A2 (en
Inventor
Garth Boehm
Josephine Dundon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Products LLC
Original Assignee
Alpharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpharma Inc filed Critical Alpharma Inc
Priority to CA002551946A priority Critical patent/CA2551946A1/en
Priority to EP04812588A priority patent/EP1763337A2/en
Publication of WO2005065661A2 publication Critical patent/WO2005065661A2/en
Publication of WO2005065661A3 publication Critical patent/WO2005065661A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Galantamine formulations, including sustained-release and fast dissolve formulations, are described.
PCT/US2004/040109 2003-12-31 2004-12-01 Immediate, controlled and sustained release formulations of galanthamine Ceased WO2005065661A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002551946A CA2551946A1 (en) 2003-12-31 2004-12-01 Immediate, controlled and sustained release formulations of galantamine
EP04812588A EP1763337A2 (en) 2003-12-31 2004-12-01 Immediate, controlled and sustained release formulations of galanthamine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53357103P 2003-12-31 2003-12-31
US60/533,571 2003-12-31

Publications (2)

Publication Number Publication Date
WO2005065661A2 WO2005065661A2 (en) 2005-07-21
WO2005065661A3 true WO2005065661A3 (en) 2005-10-06

Family

ID=34748919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/040109 Ceased WO2005065661A2 (en) 2003-12-31 2004-12-01 Immediate, controlled and sustained release formulations of galanthamine

Country Status (4)

Country Link
US (1) US20050191349A1 (en)
EP (1) EP1763337A2 (en)
CA (1) CA2551946A1 (en)
WO (1) WO2005065661A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
EA011446B1 (en) * 2004-06-17 2009-02-27 Форест Лэборэтериз, Инк. Preparatory solid oral dosage form of memantine with modified release
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
WO2006013546A2 (en) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Process for the preparation of pure galantamine
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP2623099A1 (en) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition and method for treating neurological disease
MX2007007836A (en) * 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Method for stabilizing anti-dementia drug.
ATE481096T1 (en) 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING CNS DISEASES
CN101166543B (en) * 2005-04-28 2014-07-16 卫材R&D管理有限公司 Composition containing anti-dementia drug
JP2007031407A (en) * 2005-07-29 2007-02-08 Shin Etsu Chem Co Ltd Low-substituted cellulose ether-containing coating composition and film coating preparation with unpleasant taste masked
WO2007029081A1 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Galantamine-containing controlled release oral dosage forms, processes for the preparation thereof and use for the manufacture of a medicament
US20070092568A1 (en) * 2005-10-10 2007-04-26 Gore Subhash P Galantamine compositions
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
HUE029173T2 (en) * 2006-04-26 2017-02-28 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2008062426A2 (en) * 2006-08-02 2008-05-29 Emcure Pharmaceuticals Limited Formulation of benzazepine derivatives
US7955622B2 (en) 2006-10-13 2011-06-07 Actavis Group Ptc Hf Controlled-release galantamine formulations
KR20090088913A (en) * 2006-11-21 2009-08-20 맥네일-피피씨, 인코포레이티드 Modified Release Analgesic Suspensions
DE102006056697A1 (en) * 2006-11-30 2008-06-05 Ratiopharm Gmbh Galanthamine controlled release drug
JP2010518021A (en) * 2007-01-31 2010-05-27 メチレーション・サイエンシーズ・インターナショナル・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ Sustained release pharmaceutical formulation of S-adenosylmethionine
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20090197824A1 (en) * 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
KR100782310B1 (en) 2007-03-22 2007-12-06 현대약품 주식회사 Pharmaceutical composition comprising galantamine or a pharmaceutically acceptable salt thereof
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
AU2008286914B2 (en) 2007-08-13 2014-10-02 Ohemo Life Sciences Inc. Abuse resistant drugs, method of use and method of making
WO2009024858A1 (en) * 2007-08-22 2009-02-26 Aurobindo Pharma Limited Controlled release dosage form of galantamine
AU2008302190A1 (en) * 2007-09-18 2009-03-26 Stephen Wills Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors
EP2044933A1 (en) * 2007-10-05 2009-04-08 KRKA, D.D., Novo Mesto Multi particulate matrix system containing galantamine
WO2009043914A1 (en) * 2007-10-05 2009-04-09 Krka, D.D., Novo Mesto Multi particulate matrix system containing galantamine
CL2008003507A1 (en) 2007-11-26 2009-11-27 Neuroderm Ltd Pharmaceutical composition comprising nicotine and a nicotinic acetylcholine receptor (nachr) opipramol desensitization inhibitor; pharmaceutical kit; medical device; and use to treat a disease or disorder of the central or peripheral nervous system.
EP2116232B1 (en) 2008-05-09 2012-02-15 Ratiopharm GmbH Medicine containing galanthamine with controlled release
US8193217B2 (en) * 2008-08-19 2012-06-05 Scinopharm Taiwan Ltd. Polymorphic form of granisetron hydrochloride and methods of making the same
DE102008047910A1 (en) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tabletting excipient based on lactose and cellulose
WO2010103365A2 (en) * 2009-03-09 2010-09-16 Council Of Scientific & Industrial Research Sustained release composition of therapeutic agent
US20100297232A1 (en) * 2009-05-19 2010-11-25 Monosol Rx, Llc Ondansetron film compositions
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
US8329208B2 (en) * 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
CA2994873A1 (en) * 2009-12-02 2011-06-09 Adamas Pharma, Llc Amantadine compositions and methods of use
BRPI1005440A2 (en) * 2010-01-26 2016-03-08 Hyundai Pharm Co Ltd pharmaceutical matrix composition
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
WO2012068076A2 (en) * 2010-11-15 2012-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations containing soluble drugs
JP5877935B2 (en) 2012-10-17 2016-03-08 メチレーション・サイエンシーズ・インターナショナル・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティＭｅｔｈｙｌａｔｉｏｎ Ｓｃｉｅｎｃｅｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｓｒｌ Composition comprising S-adenosylmethionine and gallic acid ester
US20140275149A1 (en) * 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
BR112018071518A2 (en) 2016-04-22 2019-02-19 Receptor Life Sciences, Inc. fast-acting herbal medicinal compounds and nutritional supplements
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
WO2017192921A1 (en) 2016-05-05 2017-11-09 Monosol Rx, Llc Enhanced delivery epinephrine compositions
JP6831645B2 (en) * 2016-06-14 2021-02-17 エルメッド株式会社 Galantamine-containing pharmaceutical compositions, methods for stabilizing galantamine in pharmaceutical compositions, and galantamine stabilizers.
EA201892396A1 (en) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. QUICKLY PRODUCTIVE PLANT MEDICINES AND BIOLOGICALLY ACTIVE ADDITIVES
MX383146B (en) 2017-01-11 2025-03-13 Ferring Bv Rapidly disintegrating pharmaceutical composition.
EP3883595A4 (en) 2018-11-19 2022-12-14 Receptor Holdings, Inc. N-ACYLATED N-FATTY AMINO ACIDS FOR REDUCING ABSORPTION VARIABILITY IN CANNABINOID COMPOSITIONS
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment
WO2024238657A2 (en) 2023-05-15 2024-11-21 Bonafide Health, Llc Sleep-improving compositions and methods of use
US12208167B1 (en) * 2024-02-06 2025-01-28 Alpha Cognition Inc. Coated tablets for pH-dependent release of benzgalantamine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038686A1 (en) * 1998-12-24 2000-07-06 Janssen Pharmaceutica N.V. Controlled release galantamine composition
US6099863A (en) * 1996-06-14 2000-08-08 Janssen Pharmaceutica N.V. Fast-dissolving galanthamine hydrobromide tablet
WO2001030318A1 (en) * 1999-10-26 2001-05-03 Janssen Pharmaceutica N.V. Oral solution containing galanthamine and a sweetening agent

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
DE4010079A1 (en) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF ALCOHOLISM
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5177070A (en) * 1991-11-15 1993-01-05 Ciba-Geigy Corporation Method of treating physiologic male erectile impotence
DE4301782C1 (en) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Use of galanthamine to treat nicotine addiction
DE4301783C1 (en) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermal system per admin. of galanthamine - esp. for treatment of Alzheimer's disease and alcohol addiction
US6316439B1 (en) * 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US5428159A (en) * 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
US5585375A (en) * 1994-07-01 1996-12-17 Davis; Bonnie M. Method for alleviating jet lag
SK283877B6 (en) * 1994-10-21 2004-04-06 Sanochemia Pharmazeutika Ag Process for producing derivatives of 4a,5,9,10,11,12,-hexahydro- 6H-benzofuro[3a,3,2-ef][2]benzazepine
US6407229B1 (en) * 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
DE19509663A1 (en) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Process for the isolation of galanthamine
GB9506843D0 (en) * 1995-04-03 1995-05-24 Chiroscience Ltd Oxidative process and products thereof
ATE204840T1 (en) * 1995-04-06 2001-09-15 Janssen Pharmaceutica Nv METHOD FOR PRODUCING GALANTHAMIN DERIVATIVES BY ASYMMETRIC REDUCTION
US5663238A (en) * 1995-07-11 1997-09-02 National Science Council Copolyesters containing naphthalene and the preparation thereof
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
GB9519268D0 (en) * 1995-09-21 1995-11-22 Chiroscience Ltd Preparation of alkaloids
GB9519267D0 (en) * 1995-09-21 1995-11-22 Chiroscience Ltd Preparation of alkaloids
GB9600080D0 (en) * 1996-01-04 1996-03-06 Chiroscience Ltd Resolution process
GB9606736D0 (en) * 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
GB9610887D0 (en) * 1996-05-24 1996-07-31 N H S Trust Process
US5965571A (en) * 1996-08-22 1999-10-12 New York University Cholinesterase inhibitors for treatment of Parkinson's disease
FR2757161B1 (en) * 1996-12-13 1999-03-12 Sanofi Sa DIPHENYLALKYL-TETRAHYDROPYRIDINES
GB9707413D0 (en) * 1997-04-11 1997-05-28 Chiroscience Ltd Process
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
CA2504349A1 (en) * 2001-11-02 2003-05-15 Diagenics International Corporation Monoclonal antibodies specific for beta-amyloid
US20040097484A1 (en) * 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
US20050142193A1 (en) * 2003-12-31 2005-06-30 Lijuan Tang Galantamine formulations
US20070092568A1 (en) * 2005-10-10 2007-04-26 Gore Subhash P Galantamine compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099863A (en) * 1996-06-14 2000-08-08 Janssen Pharmaceutica N.V. Fast-dissolving galanthamine hydrobromide tablet
WO2000038686A1 (en) * 1998-12-24 2000-07-06 Janssen Pharmaceutica N.V. Controlled release galantamine composition
WO2001030318A1 (en) * 1999-10-26 2001-05-03 Janssen Pharmaceutica N.V. Oral solution containing galanthamine and a sweetening agent

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat

Also Published As

Publication number Publication date
CA2551946A1 (en) 2005-07-21
WO2005065661A2 (en) 2005-07-21
US20050191349A1 (en) 2005-09-01
EP1763337A2 (en) 2007-03-21

Similar Documents

Publication Publication Date Title
WO2005065661A3 (en) Immediate, controlled and sustained release formulations of galanthamine
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
WO2005065645A3 (en) Donepezil formulations
WO2004080406A3 (en) Therapeutic compositions
AU2003262059A1 (en) Sustained release preparation
AU2002258563A1 (en) Pharmaceutical formulations for sustained release
WO2001078683A3 (en) Sustained release formulations comprising growth hormone
AU2001297788A1 (en) Drug release from polymer matrices through mechanical stimulation
WO2003049680A3 (en) Compositions containing both sedative and non-sedative antihistamines
WO2004091515A3 (en) iRNA CONJUGATES
WO2004062577A3 (en) Two or more enteric materials to regulate drug release
AU2002321199A1 (en) Transdermal therapeutic system (TTS) with fentanyl as active ingredient
AUPR602501A0 (en) Sustained release pharmaceutical composition
WO2006074398A3 (en) Sustained release pharmaceutical formulations comprising ranolazine
AU2002337803A1 (en) Sustained release pharmaceutical compositions
AU2003260803A1 (en) Sustained release pharmaceutical composition
AU2002354054A1 (en) Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
AU2001248772A1 (en) Sustained release drug compositions
WO2004108084A3 (en) Polymorphic forms of naltrexone
AU2001232948A1 (en) Controlled release of drugs
WO2003041656A3 (en) Soluble drug extended release system
AU2003273577A1 (en) Suicide tetramers comprising mhc class i and uses thereof
WO2002034240A3 (en) Delayed and sustained release formulations and method of use thereof
WO2005060981A3 (en) Pharmaceutical compositions
WO2002024146A3 (en) Methods of decreasing or preventing pain using spicamycin derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2551946

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 4396/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004812588

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004812588

Country of ref document: EP